Last reviewed · How we verify
NCT05616923: TOMIR
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea
Phase 1 trial testing Trametinib in Rosacea, Erythematotelangiectatic in 12 participants. Completed in 31 December 2022.
31 December 2022
Quick facts
| Lead sponsor | Albany Research Institute, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 November 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Trametinib (trametinib) — full drug profile →
Conditions studied
- Rosacea, Erythematotelangiectatic — all drugs for Rosacea, Erythematotelangiectatic →
Sponsor
Albany Research Institute, Inc.
Who can join
Adults 18 to 75, any sex, with Rosacea, Erythematotelangiectatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05616923
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Trametinib
Trials testing the same drug.
- NCT05275374 — XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation · Phase 1, PHASE2 · not yet recruiting
- NCT07110246 — Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · Phase 2 · recruiting
- NCT07010393 — Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · Phase 4 · not yet recruiting
- NCT06962254 — Imatinib and Trametinib for KRAS-mutated Solid Tumor · Phase 1 · recruiting
- NCT06119789 — Precision Cancer Therapy in Rare Cancers · Phase 2 · recruiting
Other recruiting trials for Rosacea, Erythematotelangiectatic
Currently open trials in the same condition.
- NCT06801717 — Rosacea Radiofrequency Microneedling · NA · recruiting
Other Albany Research Institute, Inc. trials
Trials by the same sponsor.
- NCT05895318 — Perceptions of MDMA-Assisted Therapy Among Veterans With PTSD · completed
- NCT02972996 — Blueberry Consumption and Type 2 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05616923 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Albany Research Institute, Inc.
- Last refreshed: 30 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05616923.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing